MICHAEL RAIDA: Open Payments
NPI 1518910389 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,477 in 59 payments from 15 companies in 2025. Trend: 2023 $1,736 · 2024 $1,995 · 2025 $1,477
Food & beverage: $1,477
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $279 |
| ABBVIE INC. | 12 | $244 |
| Otsuka America Pharmaceutical, Inc. | 6 | $193 |
| Axsome Therapeutics, Inc. | 4 | $116 |
| Almatica Pharma LLC | 4 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| E.R. Squibb & Sons, L.L.C. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Janssen Pharmaceuticals, Inc | 2 | $68 |
| Corium, LLC | 2 | $64 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Auvelity, LOREEV XR, TRINTELLIX, COBENFY, FANAPT.
Industry payments across IL — which companies pay providers there.
